Orthotype™ Pre‑Operative Screening

Pre‑operative genetic risk stratification to improve outcomes after arthroplasty.

Orthotype™ identifies patients at increased risk of poorer outcomes following arthroplasty—before surgery—supporting informed implant selection and more predictable results.
‍

Request Clinical Information

At-a-glance

Risk stratification before surgery to support informed implant selection.

‍Independent predictor of Oxford Knee Scores in published clinical research.

‍Routine workflow: blood or saliva sample, ~2‑week turnaround, MHRA registered.

THE OUTCOMES GAP

Why do arthroplasty outcomes remain variable?

Despite advances in implant design and surgical technique, 10–25% of joint replacement patients—particularly knee patients—report chronic pain and reduced function following technically successful surgery.

Key Insight
In many cases, no clear mechanical cause is identified, limiting earlyintervention.

CLINICAL REALITY

Poor outcomes often occur without implant failure.

Persistent pain and dissatisfaction are frequently seen in unrevised patients. Younger age at surgery and unexplained pain remain key drivers of suboptimal patient-reported outcomes.

Key Insight
Current pre-operative assessment does not fully explain outcome variability.

OUTCOMES EVIDENCE

Patient genotype is independently associated with post-operative outcomes.

Clinical research demonstrates that genetic risk is a significant predictor of Oxford Knee Scores—independent of age, BMI, implant duration, and metal ion levels.

Evidence Highlights
• Higher genetic reactivity scores (GRS) were associated with significantlylower PROMs
• In low-wear implants, genotype was the only significant predictor of pooreroutcomes

WHAT ORTHOTYPE™ DELIVERS

Actionable insights before surgery.

Orthotype™ identifies patients with an increased biological risk of poorer outcomes, providing stratifiable, pre-operative risk insights

Surgeons receive
• Patient-specific genetic risk
• Relative risk vs age- and sex-matched population

CLINICAL IMPACT

Supporting better first-time outcomes.

Orthotype™ enables more informed pre-operative discussions and implant selection, supporting a proactive approach to reducing the risk of suboptimal outcomes.

Outcome Benefits
• Higher likelihood of improved PROMs
• Reduced persistent, unexplained pain
• Fewer prolonged follow-up pathways

SYSTEM-LEVEL VALUE

Better outcomes, more efficient pathways.

Reducing poor outcomes improves both patient experience and healthcare system performance.

System Impact
• Fewer outpatient visits for unresolved pain
• Reduced revision pressure driven by dissatisfaction
• Improved theatre and clinic capacity utilisation

PRACTICAL ADOPTION + CTA

Designed for routine pre-operative use.

Orthotype™ integrates seamlessly into existing arthroplasty workflows.

Practical Details
• Sample: blood or saliva
• Testing: high-resolution HLA genotyping
• Turnaround: ~2 weeks
• Status: MHRA registered

DISCLAIMER

Orthotype™ provides risk stratification information to support clinical decision-making. It does not predict individual outcomes or replace clinical judgement.